691 related articles for article (PubMed ID: 17224218)
21. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
Singh HK; Chiu YL; Wilkin T
AIDS Patient Care STDS; 2015 Sep; 29(9):461-4. PubMed ID: 26153909
[No Abstract] [Full Text] [Related]
22. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
[TBL] [Abstract][Full Text] [Related]
23. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
[TBL] [Abstract][Full Text] [Related]
25. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
[TBL] [Abstract][Full Text] [Related]
26. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
Diaz-Ortega JL; Bennett JV; Castaneda D; Vieyra JR; Valdespino-Gomez JL; de Castro JF
Vaccine; 2010 Jan; 28(3):692-8. PubMed ID: 19861187
[TBL] [Abstract][Full Text] [Related]
27. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
Buxbaum S; Doerr HW; Allwinn R
Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
[TBL] [Abstract][Full Text] [Related]
28. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
[TBL] [Abstract][Full Text] [Related]
29. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
[TBL] [Abstract][Full Text] [Related]
30. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
[TBL] [Abstract][Full Text] [Related]
31. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
32. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
Jaber SM
Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
Santos EMD; Noronha TG; Alves IS; Cruz RLS; Ferroco CLV; Brum RC; Oliveira PMN; Siqueira MM; Lima MC; Ramos FLP; Bragagnolo CM; Camacho LAB; Maia MLS
Mem Inst Oswaldo Cruz; 2019 Mar; 114():e180517. PubMed ID: 30843921
[TBL] [Abstract][Full Text] [Related]
34. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
[TBL] [Abstract][Full Text] [Related]
35. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
36. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
Gatchalian S; Leboulleux D; Desauziers E; Bermal N; Borja-Tabora C
Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):589-97. PubMed ID: 15115135
[TBL] [Abstract][Full Text] [Related]
38. A combination vaccine against measles, mumps, rubella and varicella.
Knuf M; Faber J; Barth I; Habermehl P
Drugs Today (Barc); 2008 Apr; 44(4):279-92. PubMed ID: 18536786
[TBL] [Abstract][Full Text] [Related]
39. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]